Altre lingue Essex Bio-Technology Limited

Azioni

1061

KYG312371035

Mercato chiuso - Hong Kong S.E. Altri mercati azionari 10:08:20 26/04/2024			Variaz. 5gg	Var. 1 gen.
2,19 ^HKD	0,00%		-5,19%	-12,05%

18/03	Essex Bio-Technology Limited riporta i risultati degli utili per l'intero anno terminato il 31 dicembre 2023	CI
2023	Essex Bio-Technology Limited riporta i risultati degli utili per il semestre conclusosi il 30 giugno 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Essex Bio-Technology's 2023 Profit Jumps 22% on Higher Turnover	19/03
Essex Bio-Technology Posts Sound 2023 Annual Financial Results, Revenue Up 29.5%, Profit Up 22.1%	18/03
Essex Bio-Technology Limited Proposes Final Ordinary Dividend for the Financial Year Ended 31 December 2023, Payable June 17, 2024	18/03
Essex Bio-Technology Limited Reports Earnings Results for the Full Year Ended December 31, 2023	18/03
Essex Bio-Technology Limited Announces Change of Address of Head Office And principal Place of Business in Hong Kong	03/01
Essex Bio-Technology Limited(SEHK:1061) dropped from S&P Global BMI Index	18/09/23
Essex Bio-Technology's Profit Jumps 22% in H1	17/08/23
Essex Bio-Technology Posts Sound 2023 Interim Financial Results, Revenue Up 37.1%, Profit Up 22%	16/08/23
Essex Bio-Technology Limited Declares Interim Dividend for the Six Months Ended June 30, 2023, Payable on September 13, 2023	16/08/23
Essex Bio-Technology Limited Reports Earnings Results for the Half Year Ended June 30, 2023	16/08/23
Essex Bio-Technology's Ophthalmic Injection Showed Safety, Efficacy in Trial	27/07/23
The phase 1/2 clinical trial of Bevacizumab for treatment of Ophthalmic Diseases completed	26/07/23
Essex Bio-Technology Limited Provides Update on the Phase 1/2 Clinical Study in Relation to the Co-Development of the Licensed Product with Henlius for the Treatment of Exudative Age-Related Macular Degeneration	26/07/23
Essex Bio-Technology Limited Announces Early Repayment of Loan Facility	17/07/23
Essex Bio-Technology Limited commences an Equity Buyback Plan for 57,064,900 shares, representing 10% of its issued share capital, under the authorization approved on June 9, 2023.	13/06/23
Essex Bio-Technology Limited Announces Director Changes	09/06/23
Essex Bio-Technology Limited Declares Final Dividend for the Year Ended 31 December 2022	09/06/23
Essex Bio-Technology Limited's Equity Buyback announced on May 12, 2022 has expired.	09/06/23
Essex and Osteopore Entered into Exclusive Distribution Agreement	14/04/23
Essex and Osteopore Entered into Exclusive Distribution Agreement for Oral Maxillofacial products in Singapore	14/04/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Essex Bio-Technology Limited

Azioni

1061

KYG312371035

Altre lingue

Filtri